From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances


The Effect of Moxetumomab Pasudotox on Minimal Residual Disease in Hairy Cell Leukemia

Nearly two-thirds of patients with relapsed/refractory hairy cell leukemia (HCL) who were treated with the anti-CD22 recombinant immunotoxin moxetumomab pasudotox achieved complete remission (CR),...

Investigating a WT1 Peptide Vaccine in Patients With Acute Myeloid Leukemia

In an open-label, phase II study, treatment with galinpepimut-S (GPS) – a vaccine targeting the Wilms tumor 1 (WT1) protein – was well tolerated...

Ibrutinib Plus R-ICE Induces Responses in Patients With Relapsed/Refractory DLBCL

A phase I study found that adding ibrutinib to R-ICE (rituximab, ifosfamide, carboplatin, etoposide) resulted in an overall response rate of 90 percent (range...

Treatment With Blinatumomab Eradicates MRD in Patients with ALL

More than three-quarters of patients with acute lymphocytic leukemia (ALL) who were in complete remission (CR) following chemotherapy but still had evidence of minimal...

Total Metabolic Tumor Volume Predictive of Survival in Patients With Hodgkin Lymphoma

Factors with prognostic significance in early-stage Hodgkin lymphoma (HL) include bulky disease, number of regions involved, advanced age, and the presence of B symptoms....

Monitoring Pre-Malignant Clones May Predict Development of Therapy-Related Myeloid Neoplasms

Post-transplant development of therapy-related myeloid neoplasms (tMNs) originates in hematopoietic stem cells (HSCs) with tMN mutations that are present years before disease onset, according...

Ibrutinib Treatment May Predispose to Fungal Infections, Study Cautions

Although previous research has demonstrated that ibrutinib is associated with fewer infectious complications than standard chemotherapy in patients with chronic lymphocytic leukemia (CLL), a...

Understanding Bone Disease and Fractures in Patients With MGUS

Patients with monoclonal gammopathy of undetermined significance (MGUS; a precursor to multiple myeloma and other lymphoproliferative disorders) are known to be at an...

Can AMT-060 Gene Therapy FIX Hemophilia B?

After a single infusion of AMT-060 (an adeno-associated virus-5 vector carrying a corrected human factor IX gene), patients with hemophilia B experienced...

Early-Phase Study Finds Duvelisib Active in Variety of Advanced Hematologic Malignancies

The oral phosphoinositide 3-kinase (PI3K) dual inhibitor duvelisib appeared to be active and tolerable at a range of doses and across a variety of...

Current Issue

March 2018, Volume 4, Issue 4

This issue features a debate over whether CPX-351 can be used with other therapies in AML, a look at contract research organizations, and more.